Scholarlink

Background <p>Excision followed by radiofrequency ablation (eRFA) is an intraoperative method that utilizes intracavitary hyperthermia to create an additional tumor-free zone around the lumpectomy cavity in patients with breast cancer, similar to partial breast irradiation. We hypothesized that intraoperative eRFA extends the “final” tumor-free margin, decreases local recurrence, and maintains cosmesis without the need for radiation (XRT).</p> Patients and Methods <p>Patients with unifocal ER+PR+HER2− or DCIS tumors less than or equal to 3 cm with clinically negative nodes were included. After standard lumpectomy, the RFA probe was deployed 1 cm circumferentially into the walls of the lumpectomy cavity. RFA was performed at 100°C for 15 min, followed by validated intraoperative Doppler sonography. Pain and cosmesis were assessed with the Radiation Therapy Oncology Group (RTOG) scales.</p> Results <p>A total of 242 subjects were accrued to the study, with a median follow-up of 44 months (range 12–96 months); 60% were invasive ductal cancer (IDC), and 33% were ductal carcinoma in situ (DCIS). The average size was 1.1 ± 0.6 cm (0.2–3 cm). Reexcision for positive margins was &lt; 5%. In-breast recurrence rate was 2.9%. Breast pain at 6 months was 19% with RFA combined with XRT versus 1.7% with RFA alone (<i>p</i> &lt; 0.05). Cosmesis was good or excellent in 89% of subjects.</p> Conclusions <p>A majority of the subjects avoided whole breast XRT and mastectomy. Results indicate that eRFA, in lieu of XRT, is safe and effective, resulting in ~fivefold lower pain. By completing therapy in the operating room, eRFA can potentially enhance patient access and compliance, alleviate financial stress, and deliver superior cosmetic and quality-of-life outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prospective Phase II Multicenter Trial of Ablation after Breast Lumpectomy Added To Extend (ABLATE) Intraoperative Margins for the Sole Local Treatment of Breast Cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月18日

查看全文
  • Kristalyn Gallagher,
  • Sheldon Feldman,
  • Julie Barone,
  • Joshua Mammen,
  • Robert Barone,
  • Daniela Ochoa,
  • Marilee McGinness,
  • Thomas Frazer,
  • Rebecca Viscusi,
  • Julie E. Lang,
  • Jeannette Lee,
  • Laura L. Adkins,
  • Sherry Johnson,
  • Ronda Henry-Tillman,
  • Soheila Korourian,
  • V. Suzanne Klimberg

摘要

Background

Excision followed by radiofrequency ablation (eRFA) is an intraoperative method that utilizes intracavitary hyperthermia to create an additional tumor-free zone around the lumpectomy cavity in patients with breast cancer, similar to partial breast irradiation. We hypothesized that intraoperative eRFA extends the “final” tumor-free margin, decreases local recurrence, and maintains cosmesis without the need for radiation (XRT).

Patients and Methods

Patients with unifocal ER+PR+HER2− or DCIS tumors less than or equal to 3 cm with clinically negative nodes were included. After standard lumpectomy, the RFA probe was deployed 1 cm circumferentially into the walls of the lumpectomy cavity. RFA was performed at 100°C for 15 min, followed by validated intraoperative Doppler sonography. Pain and cosmesis were assessed with the Radiation Therapy Oncology Group (RTOG) scales.

Results

A total of 242 subjects were accrued to the study, with a median follow-up of 44 months (range 12–96 months); 60% were invasive ductal cancer (IDC), and 33% were ductal carcinoma in situ (DCIS). The average size was 1.1 ± 0.6 cm (0.2–3 cm). Reexcision for positive margins was < 5%. In-breast recurrence rate was 2.9%. Breast pain at 6 months was 19% with RFA combined with XRT versus 1.7% with RFA alone (p < 0.05). Cosmesis was good or excellent in 89% of subjects.

Conclusions

A majority of the subjects avoided whole breast XRT and mastectomy. Results indicate that eRFA, in lieu of XRT, is safe and effective, resulting in ~fivefold lower pain. By completing therapy in the operating room, eRFA can potentially enhance patient access and compliance, alleviate financial stress, and deliver superior cosmetic and quality-of-life outcomes.